Hildur H.
- Country
- Sweden
- Department
- Onkologiska kliniken
Research Overview
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- Percutaneous Hepatic Perfusion with Melphalan Plus Ipilimumab and Nivolumab Versus Ipilimumab and Nivolumab in Uveal Melanoma Liver Metastases
Data & Insights
Has run more than one trial at 72 of 141 partner sites.
Specializations
Advanced Melanoma Management
This investigator specializes in the treatment of metastatic and unresectable melanoma, with particular expertise in both systemic and targeted therapeutic approaches.
- Uveal Melanoma Liver Metastases
- Previously Untreated Metastatic Melanoma
- High-risk Resected Melanoma
The investigator explores innovative treatment combinations for patients with advanced disease stages.
Immunotherapy Applications
Focused on advancing immune checkpoint inhibitor therapies, particularly in the context of combination treatment strategies for melanoma.
- Anti-PD-1 Therapeutics
- Combined CTLA-4/PD-1 Blockade
- Novel Immunotherapy Combinations
The investigator evaluates various administration routes and combination approaches for immunotherapy agents.
Surgical Oncology Integration
Specializes in neoadjuvant and adjuvant treatment approaches for surgical melanoma patients, with emphasis on stage III-IV disease.
- Resectable Stage III Melanoma
- Post-surgical Adjuvant Therapy
- Neoadjuvant Treatment Strategies
The investigator studies treatment optimization for completely resected melanoma cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.